Rasha E.: Exploring Polycythemia Vera – Beyond the Hematocrit
Rasha E., Senior Clinical Pharmacist and Pharmacy Training Program Director at Abu Dhabi Stem Cells Center (ADSCC), shared a post on LinkedIn:
“Polycythemia Vera (PV): Beyond the Hematocrit
A valuable review from Hemostasis Today highlighting an important aspect of Polycythemia Vera management: thrombosis prevention requires more than simply treating the acute event.
PV is a chronic myeloproliferative neoplasm associated with a significant risk of both arterial and venous thrombosis.
Key clinical takeaways:
- Maintaining hematocrit <45% remains a cornerstone of thrombosis prevention.
- Following VTE, anticoagulation should be individualized according to the clinical scenario and patient-specific bleeding/thrombotic risks.
- The need for concomitant aspirin should be carefully reassessed when therapeutic anticoagulation is initiated.
- Appropriate cytoreductive therapy plays an important role in high-risk patients and secondary prevention.
- Unexplained splanchnic vein thrombosis should prompt consideration of an underlying myeloproliferative neoplasm, including JAK2-mutated PV.
- Emerging therapies such as rusfertide may offer additional options for controlling erythrocytosis and reducing phlebotomy requirements.
My takeaway:
The goal is not simply to treat the clot – it is to control the underlying disease, reduce recurrent thrombotic risk, and optimize long-term outcomes.
This is where multidisciplinary collaboration between hematology, clinical pharmacy, and thrombosis specialists can make a meaningful difference.
An excellent resource for clinicians managing patients with PV and thrombotic complications.
Source: Hemostasis Today – Anticoagulation and Contemporary Secondary Prevention of Thrombosis in Polycythemia Vera.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 17:11Owen McCarty: Understanding Prekallikrein and Its Role in Inflammation and Thrombosis
-
Oct 18, 2026, 17:04Emna Gouider Belhadjali: Don’t Miss GPAS 2026 on Bleeding Disorders
-
Oct 18, 2026, 16:53Mehran Ghasemzadeh: Microparticle-Associated Mitochondrial DNA in Stored Platelet Products
-
Oct 18, 2026, 16:38Edward Lee Carter: A 15-Minute Blood Test for Brain Hemorrhage?
-
Oct 18, 2026, 16:29Patrick Taylor: Oral vs Transdermal Estrogen and Cardiovascular Risk in Menopausal Women
-
Oct 18, 2026, 16:19Artangela Henry: A Meaningful Week at the SCDAA National Convention
-
Oct 18, 2026, 16:04Emília Araújo։ New Insights Into the Genetics of Hemophilia B Leyden
-
Oct 18, 2026, 15:43André Marcel Harris: Award-Winning Research on Texas Sickle Cell Data Collection
-
Oct 18, 2026, 15:21Eleonora Gambineri: First Results of the IEI-Haem Consortium at ESID 2026